Prospects for the Treatment of Multiple Sclerosis

Wynn D.R. , Rodriguez M. , O'Fallon W.M. , Kurland L.T. A reappraisal of the epidemiology of multiple sclerosis in Olmsted County, Minnesota. Neurology 1990; 40: 780–6

Hughes R.A.C. Guillain–Barré Syndrome. Heidelberg: Springer Verlag, 1990

Rose A.S. , Kuzma J.W. , Kurtzke J.F. , Namerow N.S. , Sibley W.A. , Tourtellotte W.W. Cooperative study in the evaluation of therapy in multiple sclerosis: ACTH versus placebo. Neurology (Minneap) 1970; 20(Suppl): 1–59

Milligan N.M. , Newcombe R. , Compston D.A.S. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis. 1. Clinical effects. J Neurol Neurosurg Psychiatry 1987; 50: 511–16

Thompson A.J. , Kennard C. , Swash M. Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS. Neurology 1989; 39: 969–71

Penn R.D. , Savoy S.M. , Corcos D. , Latash M. , Gottlieb G. , Parke B. , Kroin J.S. Intrathecal baclofen for severe spinal spasticity. N Engl J Med 1989; 320: 1517–21

Bever CT Jr. , Leslie J. , Camenga D.L. , Panitch H.S. , Johnson K.P. Preliminary trial of 3,4-diaminopyridine in patients with multiple sclerosis. Ann Neurol 1990; 27: 421–7

Ormerod I.E.C. , Miller D.H. , McDonald W.I. The role of NMR imaging in the assessment of MS and isolated neurological lesions. Brain 1987; 110: 1579–616

Hauser S.L. , Dawson D.M. , Lehrich J.R. Intensive immunosuppression in progressive multiple sclerosis: a randomised three-arm study of high dose intravenous cyclophosphamide, plasma exchange and ACTH. N Engl J Med 1983; 308: 173–80

Cook S.D. , Devereux C. , Troiano R. Effect of total lymphoid irradiation in chronic progressive multiple sclerosis. Lancet 1986; i: 1405–8

Cook S.D. , Troiano R. , Zito G. Deaths after total lymphoid irradiation in multiple sclerosis. Lancet 1989; ii: 277–8

The Multiple Sclerosis Study Group. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: A randomized, double-blinded, placebo-controlled clinical trial. Ann Neurol 1990; 27: 591–605

Rudge P. , Koetsier J.C. , Mertin J. , Beyer J.O.M. , van Walbeek H.K. , Clifford-Jones R. Randomised double blind controlled trial of cyclosporin in multiple sclerosis. J Neurol Neurosurg Psychiatry 1989; 52: 559–65

British and Dutch Multiple Sclerosis Azathioprine Trial Group. Double-masked trial of azathioprine in multiple sclerosis. Lancet 1988; 179–83

Kinlen L.J. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 1985; 78 (suppl A): 44–9

Soulillou J.P. , Cantarovich D. , Le Mauff B. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med 1990; 322: 1175–82

Heber-Katz E. , Acha-Orbea H. The V-region hypothesis: evidence from autoimmune encephalomyelitis. Immunology Today 1989; 10: 164–9

Acha-Orbea H. , Mitchell D.J. , Timmermann L. Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention. Cell 1988; 54: 263–73

Wraith D.C. , Smilek D.E. , Mitchell D.J. , Steinman L. , McDevitt H.O. Antigen recognition in autoimmune encephalomyelitis and the potential for peptidemediated immunotherapy. Cell 1989; 59: 247–55

Urban J.L. , Horvath S.J. , Hood L. Autoimmune T cells: immune recognition of normal and variant peptide epitopes and peptide-based therapy. Cell 1989; 59: 257–71

H-P Hartung , Schafer B. , Heininger K. , Stoll G. , Toyka K.V. The role of macrophages and eicosanoids in the pathogenesis of experimental allergic neuritis. Brain 1988; 111: 1039–59

Brown J.R. , Beebe G.W. , Kurtzke J.F. , Loewenson R.B. , Silberberg D.H. , Tourtellotte W.W. The design of clinical studies to assess therapeutic efficacy in multiple sclerosis. Neurology 1979; 29: 3–23

McKhann G.M. The trials of clinical trials. Arch Neurol 1989; 46: 611–14

Noseworthy J.H. , Vandervoort M.K. , Wong C.J. , Ebers G.C. Canadian Cooperative MS Study Group. Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. Neurology 1990; 40: 971–5

Willoughby E.W. , Paty D.W. Scales for rating impairment in multiple sclerosis: A critique. Neurology 1988; 38: 1793–8